1. Smith MA, Ries LA, Gurney JG, et al. Leukemia.
In Ries LA, Smith MA, Gurney JG, et al. eds. Cancer Incidence
and Survival among Children and Adolescents: United States SEER
Program 1975-1995. Bethesda, MD: National Cancer Institute,
SEER Program; 1999. NIH Pub. No. 99-4649, 17-34.
2. McNeil DE, Cote TR, Clegg L, Mauer A. SEER update of incidence
and trends in pediatric malignancies: acute lymphoblastic leukemia. Med
Pediatr Oncol. 2002;39(6):554-557; discussion 552-553.
3. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N
Engl J Med. 2006;354(2):166-178.
4. Gaynon PS, Trigg ME, Heerema NA, et al. Children’s
Cancer Group trials in childhood acute lymphoblastic leukemia: 1983-1995. Leukemia. 2000;14(12):2223-2233.
5. Schrappe M, Reiter A, Ludwig WD, et al. Improved outcome
in childhood acute lymphoblastic leukemia despite reduced use of
anthracyclines and cranial radiotherapy: results of trial ALL-BFM
90. German-Austrian-Swiss ALL-BFM Study Group. Blood. 2000;95(11):3310-3322.
6. Moghrabi A, Levy DE, Asselin B, et al. Results of the Dana-Farber
Cancer Institute ALL Consortium Protocol 95-01 for children with
acute lymphoblastic leukemia. Blood. 2007;109(3):896-904.
7. Schultz KR, Pullen DJ, Sather HN, et al. Risk- and response-based
classification of childhood B-precursor acute lymphoblastic leukemia:
a combined analysis of prognostic markers from the Pediatric Oncology
Group (POG) and Children’s Cancer Group (CCG). Blood. 2007;109(3):926-935.
8. Nachman JB, Heerema NA, Sather H, et al. Outcome of treatment
in children with hypodiploid acute lymphoblastic leukemia. Blood.
2007;110(4): 1112-1115.
9. Arico M, Valsecchi MG, Camitta B, et al. Outcome of treatment
in children with Philadelphia chromosome-positive acute lymphoblastic
leukemia. N Engl J Med. 2000;342(14):998-1006.
10. Uckun FM, Sensel MG, Sather HN, et al. Clinical significance
of translocation t(1;19) in childhood acute lymphoblastic leukemia
in the context of contemporary therapies: a report from the Children’s Cancer
Group. J Clin Oncol. 1998;16(2):527-535.
11. Breit S, Stanulla M, Flohr T, et al. Activating NOTCH1 mutations
predict favorable early treatment response and long-term outcome
in childhood precursor T-cell lymphoblastic leukemia. Blood. 2006;108(4):1151-1157.
12. Pui CH, Rubnitz JE, Hancock ML, et al. Reappraisal
of the clinical and biologic significance of myeloid-associated
antigen expression in childhood acute lymphoblastic leukemia. J
Clin Oncol. 1998;16(12):3768-3773.
13. Moricke A, Zimmermann M, Reiter A, et al. Prognostic impact
of age in children and adolescents with acute lymphoblastic leukemia:
data from the trials ALL-BFM 86, 90, and 95. Klin Padiatr. 2005;217(6):310-320.
14. Pui CH, Gaynon PS, Boyett JM, et al. Outcome of treatment
in childhood acute lymphoblastic leukaemia with rearrangements of
the 11q23 chromosomal region. Lancet. 2002;359(9321):1909-1915.
15. Pui CH, Sandlund JT, Pei D, et al. Results
of therapy for acute lymphoblastic leukemia in black and white children. JAMA. 2003;290(15):2001-2007.
16. Hijiya N, Liu W, Sandlund JT, et al. Overt testicular disease
at diagnosis of childhood acute lymphoblastic leukemia: lack of
therapeutic role of local irradiation. Leukemia. 2005;19(8):1399-1403.
17. Gaynon PS, Desai AA, Bostrom BC, et al. Early response to
therapy and outcome in childhood acute lymphoblastic leukemia: a
review. Cancer. 1997;80(9):1717-1726.
18. Nachman JB, Sather HN, Sensel MG, et al. Augmented post-induction
therapy for children with high-risk acute lymphoblastic leukemia
and a slow response to initial therapy. N Engl J Med. 1998;338(23):1663-1671.
19. van Dongen JJ, Seriu T, Panzer-Grumayer ER, et al. Prognostic
value of minimal residual disease in acute lymphoblastic leukaemia
in childhood. Lancet. 1998;352(9142):1731-1738.
20. Borowitz MJ, Devidas M, Hunger SP, et al. Clinical significance
of minimal residual disease in childhood acute lymphoblastic leukemia
and its relationship to other prognostic factors: a Children’s
Oncology Group study. Blood. Jun 15 2008;111(12):5477-5485.
21. Coiffier B, Altman A, Pui CH, Younes A, Cairo MS. Guidelines
for the management of pediatric and adult tumor lysis syndrome:
an evidence-based review. J Clin Oncol. 2008;26(16):2767-2778.
22. Goldie JH, Coldman AJ. A mathematic model for relating the
drug sensitivity of tumors to their spontaneous mutation rate. Cancer
Treat Rep. 1979;63(11-12):1727-1733.
23. Simon R, Norton L. The Norton-Simon hypothesis: designing
more effective and less toxic chemotherapeutic regimens. Nat
Clin Pract Oncol. 2006;3(8):406-407.
24. Riehm H, Gadner, H., Henze, G., Langermann, H.J., Odenwald,
E. The Berlin childhood acute lymphoblastic leukemia therapy study,
1970-1976. Am J Pediatr Hematol Oncol. 1980;2(299).
25. Gaynon PS, Steinherz PG, Bleyer WA, et al. Improved therapy
for children with acute lymphoblastic leukemia and unfavorable presenting
features: a follow-up report of the Children’s Cancer Group
Study CCG-106. J Clin Oncol. 1993;11(11):2234-2242.
26. Tubergen DG, Gilchrist GS, O’Brien RT, et al. Improved
outcome with delayed intensification for children with acute lymphoblastic
leukemia and intermediate presenting features: a Children’s
Cancer Group phase III trial. J Clin Oncol. 1993;11(3):527-537.
27. Seibel NL, Steinherz PG, Sather HN, et al.
Early postinduction intensification therapy improves survival for
children and adolescents with high-risk acute lymphoblastic leukemia:
a report from the Children’s Oncology Group. Blood. 2008;111(5):2548-2555.
28. Bostrom BC, Sensel MR, Sather HN, et al.
Dexamethasone versus
prednisone and daily oral versus weekly intravenous mercaptopurine
for patients with standard-risk acute lymphoblastic leukemia: a report
from the Children’s Cancer Group.
Blood. 2003;101(10):3809-3817.
29. Mattano LA, Jr., Sather HN, Trigg ME, Nachman JB. Osteonecrosis
as a complication of treating acute lymphoblastic leukemia in children:
a report from the Children’s Cancer Group. J Clin
Oncol. 2000;18(18):3262-3272.
30. Jansen NC, Kingma A, Schuitema A, et al. Post-treatment
intellectual functioning in children treated for acute lymphoblastic
leukaemia (ALL) with chemotherapy-only: a prospective, sibling-controlled
study. Eur J Cancer. 2006;42(16):2765-2772.
31. von der Weid N, Mosimann I, Hirt A, et al. Intellectual
outcome in children and adolescents with acute lymphoblastic leukaemia
treated with chemotherapy alone: age- and sex-related differences. Eur
J Cancer. 2003;39(3):359-365.
32. Bhatia S, Sather HN, Pabustan OB, Trigg ME, Gaynon PS, Robison
LL. Low incidence of second neoplasms among children diagnosed with
acute lymphoblastic leukemia after 1983. Blood. 2002;99(12):4257-4264.